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Abstract
Background: With a decline in malaria burden, innovative interventions and tools are required to reduce malaria transmission
further. Mass drug administration (MDA) of artemisinin-based combination therapy (ACT) has been identified as a potential tool
to further reduce malaria transmission, where coverage of vector control interventions is already high. However, the impact is
limited in time. Combining an ACT with an endectocide treatment that is able to reduce vector survival, such as ivermectin (IVM),
could increase the impact of MDA and offer a new tool to reduce malaria transmission.
Objective: The study objective is to evaluate the impact of MDA with IVM plus dihydroartemisinin-piperaquine (DP) on malaria
transmission in an area with high coverage of malaria control interventions.
Methods: The study is a cluster randomized trial in the Upper River Region of The Gambia and included 32 villages (16 control
and 16 intervention). A buffer zone of ~2 km was created around all intervention clusters. MDA with IVM plus DP was implemented
in all intervention villages and the buffer zones; control villages received standard malaria interventions according to the Gambian
National Malaria Control Program plans.
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Results: The MDA campaigns were carried out from August to October 2018 for the first year and from July to September
2019 for the second year. Statistical analysis will commence once the database is completed, cleaned, and locked.
Conclusions: This is the first cluster randomized clinical trial of MDA with IVM plus DP. The results will provide evidence
on the impact of MDA with IVM plus DP on malaria transmission.
Trial Registration: ClinicalTrials.gov NCT03576313; https://clinicaltrials.gov/ct2/show/NCT03576313
International Registered Report Identifier (IRRID): DERR1-10.2196/20904
(JMIR Res Protoc 2020;9(11):e20904) doi: 10.2196/20904
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Introduction
Between 2000 and 2015, the burden of malaria decreased
substantially in sub-Saharan Africa following the scale-up of
insecticide-treated bed nets (ITNs), indoor residual spraying
(IRS), and artemisinin-based combination therapy [1,2]. In The
Gambia, between 2003 and 2007, the proportion of blood slides
positive for malaria decreased by 74%, and hospital admissions
for malaria by 81% [3,4]. Nevertheless, despite the high
coverage of control interventions, malaria transmission has
become increasingly heterogeneous [5-7]. Innovative
interventions and tools to further reduce transmission and
eliminate malaria are needed.
Mass drug administration (MDA), a full antimalarial treatment
to all inhabitants of target communities regardless of their
infection status, has been identified as a potential tool to further
reduce transmission where coverage of vector control
interventions is already high [8,9]. MDA with artemisinin-based
combination therapy (ACT) reduces transmission by clearing
asexual infections and early-stage gametocytes in asymptomatic,
infected individuals [8,9]. Dihydroartemisinin-piperaquine (DP),
thanks to its simple dosing schedule, long posttreatment
prophylaxis period, good safety profile [10,11], and the fact
that it is not used as a first-line antimalarial treatment in The
Gambia, is a promising candidate for MDA. However, the effect
of MDA with ACT on malaria is limited over time [12,13]. This
limited impact is largely attributed to incomplete coverage and
the persistence of malaria parasites in the mosquito population,
with a smaller contribution to residual transmission of
gametocytes remaining after ACT administration [14].
Combining an antimalarial treatment (DP) with an endectocide
treatment able to reduce vector survival, ivermectin (IVM),
could increase the impact of MDA and offer a new tool to reduce
malaria transmission [15,16]. IVM is a broad-spectrum
antiparasitic endectocidal drug, active against a wide range of
parasites, including ectoparasites [17]. It reduces the lifespan
of mosquitoes that feed on treated individuals [16], with
conflicting data on a possible effect on parasite development
in surviving mosquitoes [18-20]. A major advantage of IVM is
that, since malaria vectors feed on more than one person, the
effective coverage may exceed MDA coverage, especially if its
mosquitocidal effect can be extended by repeated treatments.
Repeated IVM dosing increases the duration of time that IVM
concentration remains above the lethal concentration that kills
50% of mosquitoes [17]. A 3-day regimen of IVM 300 µg/kg
is safe and has a mosquitocidal effect for Anopheles gambiae
s.s. lasting approximately 28 days post treatment [16].
The community administration of IVM could reduce malaria
transmission [19,21], providing a synergistic effect compared
to MDA with ACTs alone [15]. Furthermore, IVM can reduce
the prevalence of other parasitic infections, including
ectoparasites and soil-transmitted helminths, which could be
an important additional benefit and improve the
cost-effectiveness of this intervention.
The mass drug administration of ivermectin and
dihydroartemisinin-piperaquine as an additional intervention
for malaria elimination (MASSIV) study is a cluster randomized
trial that aims to evaluate the impact of MDA with IVM plus
DP on malaria transmission in an area with high coverage of
malaria control interventions, eg, ITNs, IRS, and seasonal
chemoprevention (SMC). The trial was implemented in Basse,
Upper River Region (URR) in The Gambia.
Study Objectives
Clinical
The clinical objective is to determine whether three monthly
rounds of MDA with IVM plus DP implemented over two
malaria transmission seasons will reduce malaria transmission
in communities with high coverage of malaria control
interventions.
Entomological
The entomological aim is to determine whether three monthly
rounds of MDA with IVM plus DP implemented over two
malaria transmission seasons will reduce vector parity, a proxy
for vector survival, in communities with high coverage of
malaria control interventions.
Social Science and Health Economics
The social science and health economics aims are to (1) identify
the most socially acceptable and sustainable way of achieving
and maintaining high coverage of MDA with IVM plus DP,
and (2) determine the costs and cost-effectiveness of this
intervention compared to standard malaria control measures.
Methods
Study Design
The study is a cluster randomized trial (ClinicalTrials.gov,
NCT03576313) that included a total of 32 villages (16 control
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and 16 intervention), located at least 3 km from each other. A
buffer zone of ~2 km was created around all intervention clusters
in a modified fried-egg design [22]. No buffer zone was created
around control villages. MDA with IVM plus DP was
implemented in all intervention villages and the buffer zones;
control villages received standard malaria interventions
according to the Gambian National Malaria Control Program’s
(NMCP) plans.
Study Setting
The study was conducted in the eastern part of The Gambia in
the Upper River Region (URR). The region is open Sudanese
savanna and covers an area of 1995 km2 [23]. Most of the
residents are subsistence farmers. The climate is characterized
by a long dry season from mid-October to mid-June, followed
by a single short rainy season. Malaria transmission is highly
seasonal, with most malaria cases occurring during the rainy
season and immediately afterward, until December-January
[23,24]. Malaria transmission has decreased substantially in
The Gambia; however, it is higher in URR than in other regions
[24]. The URR is also characterized by low vector density and
high vector parity rate, indicating high vector survival,
suggesting the existence of populations (or subpopulations) of
mosquitoes able to escape standard vector control interventions
[24].
Selection of Villages and Informed Consent
A cross-sectional survey was carried out in November 2017, at
the peak of malaria transmission, in 47 medium-sized (200-600
inhabitants) villages to select study villages with a baseline
malaria prevalence of at least 10%. Following the survey, 32
villages with malaria prevalence determined by qPCR of at least
10% were included in the trial and randomly assigned to either
the intervention or control arm using STATA, version 15;
randomization was constrained such that the mean baseline
prevalence in the intervention clusters was within ±10% of the
prevalence in the control clusters.
After explaining the study objective and methods of the trial to
the local authorities and the populations of the study villages
through sensitization meetings in the local language, a census
of the study population was carried out in November 2017. This
was followed by individual consent procedures to obtain written
informed consent for all willing residents in the study villages.
Consent for children was provided by their parents/guardians;
assent was sought for adolescents 12-17 years old.
Consent and enrolment procedures were carried out throughout
the trial to obtain written informed consent from new residents
and individuals missed previously by the research team due to
absence at the time of the initial consenting and enrolment
procedures.
A list of all residents in the study villages, by compound,
including consent status, were generated and made available to
the study team.
Eligibility Criteria
The target population for MDA was all eligible individual
residents in the intervention villages. During each MDA round,
residents were (re)assessed for eligibility to receive IVM and
DP. Participants had to meet all inclusion criteria and none of
the exclusion criteria. Inclusion criteria were: (1)
age/anthropometry, for IVM: weight ≥15 kg; for DP: age >6
months, (2) willingness to comply with trial procedures, and
(3) individual written informed consent. The exclusion criteria
for both IVM and DP were known chronic illnesses such as
HIV, tuberculosis, hepatitis, and severe malnutrition.
Additionally, for IVM only, exclusion criteria were (1)
pregnancy (any trimester) or breastfeeding, (2) hypersensitivity
to IVM, and (3) travel to Loa loa endemic countries (Central
Africa); for DP, these were: (1) first-trimester pregnancy, (2)
hypersensitivity to DP, and (3) taking drugs that influence
cardiac function or prolong QTc interval.
Trial Medication and Intervention
DP (Guilin Pharmaceuticals, China) was available as tablets of
320/40 mg and 160/20 mg piperaquine/dihydroartemisinin per
tablet. DP was administered orally, once daily for three days,
according to body weight per manufacturer’s guidelines. For
participants unable to swallow the tablets, such as infants and
young children, DP was crushed and mixed with water. The
mixture was used immediately after preparation. If a participant
vomited within 30 minutes of taking DP, the full dose was
readministered; if a patient vomited within 30-60 minutes, half
the dose was readministered. IVM (Laboratorio Elea SACIF y
A, Argentina) was available as 6 mg tablets. It was given at
300-400 μg/kg/day once daily for three days (15.0-25.9 kg one
tablet, 26.0-40.9 kg two tablets, 41.0-60.9 kg 3 tablets, 61.0-80.9
kg four tablets, 81.0-95.9 kg five tablets, ≥96 kg 6 tablets).
Therefore, the total dose of IVM for each round was 900-1200
μg/kg. Before treatment, women of reproductive age (15-49
years) were asked to provide a urine sample to test for
pregnancy. All treatments were supervised.
MDA was implemented each year and for two consecutive
transmission seasons as three-monthly rounds starting from July
(end of the dry season) to August and September (rainy season).
The choice of implementing the intervention for two consecutive
years was taken to estimate its cumulative effect and to monitor
community participation over repeated intervention rounds.
Standard malaria control interventions were implemented in
both intervention and control villages. These consisted of ITNs,
IRS with pirimiphos-methyl (Actellic 300CS) done in mid-July
2019, just before the first MDA round of IVM and DP, prompt
diagnosis and treatment with artemether-lumefantrine, SMC,
and intermittent preventive treatment during pregnancy (IPTp).
During the three rounds of MDA, SMC was not administered
to children in the intervention villages eligible for MDA with
IVM plus DP to avoid double antimalarial treatment. In these
villages and during the MDA period, only children aged 3-6
months received SMC as they were not eligible for DP
treatment. Nevertheless, all children aged 3-59 months received
SMC one month after completing the last MDA round in
intervention villages. The implementation of these malaria
control interventions was done by the Regional Health Team
and documented at the level of individual participants. Eligible
children in control villages received SMC as planned by the
NMCP.
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Outcome Measures
Clinical
The primary clinical endpoint was the prevalence of malaria
infection measured by qPCR in all age groups [25] via a yearly
cross-sectional survey at the peak of the transmission season in
November.
Secondary endpoints included (1) incidence of clinical malaria
estimated by passive case detection by recording all clinical
cases from study villages (both intervention and control)
attending the local health facilities or the community health
worker when present; (2) prevalence of drug-resistant markers
such as Pfcrt and Pfmdr-1 mutations [26], in malaria-positive
blood samples collected during the annual cross-sectional
survey; (3) serological markers of recent malaria infection and
recent Anopheles exposure, both determined by detecting
relevant antibody responses in blood samples collected during
the annual cross-sectional survey; (4) intervention coverage as
the proportion of eligible individuals having taken the
investigational products.
Tertiary endpoints were the prevalence of bedbugs, headlice,
scabies, and soil-transmitted helminths. Surveys were done
yearly, before and after the MDA campaign.
Entomological
The primary entomological endpoint was the parous rate of An.
gambiaes.l. females in each study group, determined on
extracted ovaries [27]. The secondary endpoint was the duration
of the IVM mosquitocidal effect, determined by the mortality
of insectary colonized An. coluzzii after feeding on IVM-treated
individuals on days 7, 14, and 21 post treatment. An. coluzzii
mortality was recorded over 14 days after feeding.
Social Sciences and Economics
The economics and social sciences endpoints included: (1) MDA
participation and acceptability, and (2) MDA costs and
cost-effectiveness. For participation and acceptability,
quantitative and qualitative research methods were used. For
the former, in each intervention village, a cross-sectional survey
was conducted between MDA years 1 and 2. For qualitative
methods, in-depth interviews and focus group discussions with
MDA participants, MDA decliners, village leaders, MDA field
staff, and others were carried out throughout all trial activities.
Information on the costs of malaria episodes to households and
their management and the intervention costs was collected to
estimate costs and cost-effectiveness. From these, the
incremental cost-effectiveness ratio of the intervention versus
control was calculated as costs per malaria-related DALY
averted. Moreover, policy considerations around translating and
scaling up the intervention were explored.
Statistical Considerations
The sample size was based on two primary endpoints: malaria
prevalence determined by qPCR at the peak of the malaria
transmission season and the vector population’s parous rate.
For malaria prevalence, we assumed the mean malaria
prevalence in the control arm at peak transmission would be
15%; this is a conservative assumption, as, in November 2013,
the prevalence in villages in eastern Gambia varied between
21.3% and 44.3% [24]. Based on an initial prevalence of 15%
and assuming 95%, 86%, and 63% of eligible individuals receive
1, 2, or 3 courses of DP+IVM each year, prevalence would
decrease by >90% assuming “ideal conditions” such as the
absence of population movement, perfect adherence and no
cluster spillover effects (human/vector movement from control
to intervention clusters). However, such factors may influence
the effect size of the intervention. Therefore, we used a more
conservative effect size of 50% or prevalence from 15% to
7.5%. Assuming a conservative coefficient of variation of 0.5,
16 clusters per arm, 200 individuals per cluster recruited in the
yearly cross-sectional survey, would have 90% power to detect
a significant difference between study arms.
For the vector parous rate, the assumption was that the parous
rate of An. gambiae s.l. would be 85% because, in 2013, it was
90.7% and 81.1% in the North Bank and South Bank of the
URR, respectively [24]. Therefore, assuming the intervention
would decrease parity from 85% to 75%, and a coefficient of
variation of 0.25, dissecting 50 An. gambiae s.l per village would
have 90% power to find a significant difference between arms.
Randomization and Blinding
The unit of randomization was the village. Randomization to
the intervention or the control arm was done by computer-based
randomization. To prevent imbalance for potential confounding
factors, restricted randomization to balance the arms on factors
such as baseline prevalence, ITN coverage, and distance from
health facilities was used [22].
Considering the nature of the trial (cluster randomized), the
primary endpoint (malaria prevalence), and the logistical and
ethical (treating thousands of individuals with placebo)
challenges, we chose not to blind participating individuals. All
laboratory staff involved in processing samples and evaluations
contributing to any clinical or entomological endpoints were
blinded to the allocation arm.
Study Procedures and Evaluations
Clinical Evaluation
Passive case detection was established at local health facilities
and the village level if community health workers were present.
All suspected malaria cases, such as patients with fever or
history of fever in the last 24 h without any other apparent
illness, were investigated with an RDT (SD BIOLINE Malaria
Ag Pf Standard Diagnostics); if positive, the patient was treated
with artemether-lumefantrine, the first-line treatment in The
Gambia. Axillary body temperature was measured using an
electronic thermometer; a blood slide and blood spots were
collected for later molecular analysis. Randomly selected
individuals, regardless of temperature or history of symptoms,
were included in the cross-sectional surveys to collect blood
samples by finger prick and administer a short questionnaire
on demographic characteristics, area of residence, recent travel
history, and use of malaria control interventions and recent
history of clinical malaria.
A cross-sectional survey to estimate the prevalence of
ectoparasites, scabies, and helminths was carried out. In each
cluster, 30 children aged 4-13 years, the age group at highest
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risk of these infections, were selected. Bedbugs were detected
by visual inspection of the child’s bed using torchlight, and
headlice were detected by visual search of the scalp. Scabies
was identified by a complete physical examination of the body.
A stool sample was taken to identify the presence of helminths,
including Strongyloides stercoralis, Trichuris trichiura, Necator
americanus, Ancylostoma duodenale, and Ascaris lumbricoides
using PCR.
Entomological Evaluations
Both intensive and routine entomological surveys were
performed. Intensive surveys were carried out 7-14 days after
each MDA in all the intervention villages and for a similar
period in 8 control villages randomly selected at the beginning
of the study. The same control villages were sampled throughout
the transmission season. Collections were carried out over three
consecutive nights in six randomly selected houses. Monthly
human landing catches (indoor and outdoor) were carried out
in three houses for two nights (6 nights/month) to determine
the landing rate, parity rate, sporozoite rate, and the
entomological inoculation rate, and their potential reduction by
IVM. Four collectors rotated between indoor and outdoor sites
every 2 hours, from 7:00 pm to 7:00 am, in four selected villages
per study arm. Routine surveys were carried out monthly, after
the intensive surveys, between October and December, in all
intervention and control villages using CDC light traps. [28].
In each village, six trapping nights/month with six indoor CDC
light traps were positioned 1 m above the ground at the foot end
of the bed (1 per house and protected by ITN) to obtain estimates
of vector density, parity, and sporozoite rates. Parity was
determined by dissecting 60 unfed An. gambiae s.l. (10 per trap
per village) in droplets of phosphate-buffered saline (PBS) and
read with a microscope at 10× field magnification. Sporozoite
rate was determined by ELISA on the head and thorax of An.
gambiae s.l.
To monitor the duration of the IVM mosquitocidal effect and
potential host characteristics associated with lower efficacy, 40
randomly selected adults and 40 randomly selected children
(2-10 years old) were recruited in one intervention and one
control village near Basse field station, which has an insectary.
Children were included in this component of the study because
linear dosing based on total body weight may not achieve similar
drug exposure in children as in adults, possibly a consequence
of age-related changes in gastrointestinal motility, pH, or
prehepatic expression of metabolic enzymes or transporters,
resulting in increased absorptive capacity with age [29,30]. Only
IVM-treated individuals were selected in intervention villages;
all selected participants were asked to provide additional written
informed consent. A 3-mL blood sample was collected at 7, 14,
and 21 days post MDA. This blood sample was placed in a glass
membrane feeding system and 2 cups (250 ml, covered at the
top with netting), each containing 50 insectary-reared An.
gambiae s.s. mosquitoes, were presented to the membrane feeder
for 20 minutes [31]. The number of mosquitoes with an
engorged abdomen was counted and those with unfilled/partially
filled abdomens discarded. Mosquito survival was monitored
daily until 14 days post feeding. To further understand
heterogeneity in mosquito mortality, participants across different
age groups, gender, and varying body mass index (BMI) were
selected for these membrane feeding assays. Membrane feeding
assays were performed using insectary-reared An. coluzzii at
different age ranges.
Social Sciences Evaluations
A mixed-methods social science study was carried out prior to
and throughout the trial. This study used ethnographic,
qualitative, and quantitative methods to assess MDA coverage,
potential bottlenecks to implementation, adherence, and
acceptability among potential MDA participants. Before the
initial MDA campaign, potential bottlenecks for the intervention
were assessed, and recommendations were made to improve
implementation in the first phase. These data helped fine-tune
the intervention to local realities and engaged stakeholders to
assure participation and long-term sustainability. In the second
phase, exploratory research was conducted in all intervention
and control villages to assess the MDA’s socio-cultural effects.
Methods included observations of all trial components, in-depth
and key-informant interviews, and focus group discussions.
These methods were carried out in both the first and second
years of the MDA. A quantitative household survey was
conducted between years to assess findings from the first
intervention year in more detail; these findings were then
explored by additional qualitative and ethnographic work,
including surveys, interviews, and focus group discussions in
the second year.
Laboratory Evaluations
A finger prick blood sample was collected from all selected
individuals; 40-50 µL (3 droplets) were blotted onto Whatman
3 MM filter paper and stored with a desiccant at 4°C. For the
molecular detection of P. falciparum parasitemia, three 6-mm
punches of dried blood spot, each representing approximately
8 μL blood, were added to a 96-deep well plate and used for
DNA extraction. Extracted DNA was analyzed with varATS
qPCR using 5 μL of extracted DNA per assay [24]. All qPCR
output was analyzed using the BioRad CFX Manager software.
Each plate contains two rows of P. falciparum standard dilution,
used to make the quantification curve and allow quality control.
For the serological analysis, serum was eluted from one 6-mm
punch (~4 µL serum) from the filter paper. This punch was
eluted in 200 µL PBS/azide to have one 1:50 predilution from
which 10 µL were used on the Luminex plate. As controls for
the immunoassay, BSA-coupled beads, a pool of negative sera
(malaria naïve European sera), and positive sera (highly exposed
Gambian sera from previous surveys) were added to each plate.
Plates were analyzed and read using the MAGPIX [32]. Results
were presented as the median fluorescence intensity.
Data Capture, Management, and Analysis
Data for each participant were captured on electronic case report
forms. Informed consent, demography, medical history, physical
examination, vital signs, drug administration, adherence to study
drugs, adverse events including serious adverse events, and
laboratory evaluations were recorded.
All trial data were stored and managed within the REDCap trial
database system, an application specifically designed to collect
and store clinical trial data and customized for electronic data
capture at the trial site. Analytical results for samples from the
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prevalence surveys were linked to the main trial database. When
inconsistencies were found, these were checked against the
original forms and subsequently amended in the dataset. All
staff involved in the trial was trained on their specific tasks.
Statistical Analysis
The primary clinical endpoint, malaria prevalence at the end of
the second transmission season, will be compared between arms
using random-effects logistic regression, and a random effect
for study village will be included to account for clustering. An
odds ratio, 95% CI, and P value will be presented. Malaria
prevalence at the end of the first transmission season will be
analyzed separately and in the same way.
The primary entomological endpoint, vector parity, will be
compared between arms using random-effects logistic
regression, and a random effect for study village will be included
to account for clustering. A fixed effect for study month and
year will be included. An odds ratio, 95% CI, and P value will
be presented. Incidence will be compared between arms using
random-effects Poisson regression, and a random effect for
study village will be included to account for clustering. An
offset for village population and a fixed effect for the study year
will be included. A rate ratio, 95% CI, and P value will be
presented. Mosquito mortality, a secondary entomological
endpoint, will be determined by Kaplan-Meier estimates.
Kaplan-Meier plots of mosquito survival will be presented for
each age group and timepoint. A comparison between the arms
will be made using survival analysis with an exponential survival
model. A random effect (shared frailty) will be included for
each human participant to account for correlated outcomes on
mosquitoes fed on the same participant.
Other entomological endpoints: (1) Mosquito density will be
compared between arms using random-effects negative binomial
regression, and a random effect for study village will be included
to account for clustering. A fixed effect for study month and
year will be included. An odds ratio, 95% CI, and P value will
be presented; (2) Sporozoite rates in field-caught mosquitoes
will be compared between arms using random-effects logistic
regression, and a random effect for study village will be included
to account for clustering. A fixed effect for study month and
year will be included. An odds ratio, 95% CI, and P value will
be presented.
Quality Management
An independent data and safety monitoring board (DSMB) was
appointed to advise the sponsor and investigators on the trial’s
safety issues. Study physicians and nurses were trained to
monitor and report all adverse events, including serious adverse
events associated with treatment. Before each dose, adverse
events that occurred were systematically documented by medical
terms, start and end date, severity and seriousness, relation to
the study drug, and outcome. The relationship to the study drugs
was determined based on temporal association and clinical
judgment. The study nurses visited each household in
intervention villages 7 days after starting treatment to monitor
and document any adverse events in the study population.
Serious adverse events were reported to the DSMB, the local
ethics committee, and the London School of Hygiene and
Tropical Medicine (LSHTM) Ethics Committee. Analysis of
adverse events was restricted to the intervention arm because
the study population in the control arm was not treated with the
investigational products.
Ethical Approval
The protocol, informed consent documents, and patient
information sheets have been reviewed and approved by The
Gambia Government/MRC Joint Ethics Committee (ref number:
1593) and the London School of Hygiene and Tropical Medicine
Ethics Committee (ref number: 15823).
Results
The MDA campaigns were carried out from August to October
2018 for the first year and from July to September 2019 for the
second year. Statistical analysis will commence once the
database is completed, cleaned, and locked.
Discussion
Principal Findings
IVM is a promising tool to complement the current effort to
interrupt malaria transmission. It targets malaria vectors
regardless of biting behavior (it kills exophagic and exophilic
mosquitoes, including early biting vectors) and reduces vectorial
capacity [15,33]. Research has shown that IVM is a potentially
valuable addition to the existing tools to decrease malaria
transmission [15,16,18,33,34]. Modeling showed that three
monthly rounds of MDA with IVM at 300 μg/kg/day daily for
three days with 70% coverage would reduce clinical incidence
by 70% and prevalence by 34% in a highly seasonal moderate
transmission setting [15]. The magnitude of the impact is
predicted to be higher for MDA of IVM plus DP, resulting in
a reduction of clinical incidence by 75% and prevalence by 64%
[15]. Nevertheless, this trial compares MDA of IVM plus DP
to standard malaria control interventions and cannot distinguish
the IVM effect from the DP effect. The proposed trial will
evaluate the impact of MDA with IVM plus DP.
Cluster randomized trials are the gold standard design to assess
the community-level effect of an intervention [22]. Key
considerations for the design are cluster size, spatial separation,
and movement of individuals between intervention and control
clusters [35,36]. Individual movement could lead to
contamination or spillover, which would affect the interpretation
of the intervention’s efficacy [35]. We have defined a buffer
zone around intervention clusters to reduce the spillover effect
and ensure that intervention and control clusters are spatially
well separated. The intervention (MDA with IVM plus DP) was
carried out in intervention clusters and buffer zones to minimize
contamination of the intervention villages. The entomological
endpoint was one of the trial’s primary objectives, and buffer
zones were created to minimize contamination of intervention
villages by vectors from control villages.
Measuring and detecting changes in malaria transmission
requires appropriate metrics to assess the community-wide
impact of an intervention [37]. Several metrics measuring
different facets of malaria transmission have been proposed,
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including entomological inoculation rate, slide positivity rate,
parasite prevalence, disease incidence, sporozoite rate, vectorial
capacity, and serological markers of mosquito and malaria
exposure [37-39]. All these metrics have intrinsic limitations
to their precision and accuracy [38]. Nevertheless, parasite
prevalence is a suitable direct estimate of malaria infection in
low transmission settings [37,38].
Parasite prevalence, the metric designed to measure the
proportion of individuals found with parasites in their blood,
varies by the methods used [37], including microscopy, RDT,
and PCR [37,39]. Microscopy and RDTs may miss infections
of low parasite density that represent a large proportion of
infections in a low-transmission setting. Parasite prevalence at
the peak of the transmission season and determined by PCR
can provide an accurate estimate of the community’s parasite
reservoir and the effect of the intervention [38,40]. This trial’s
primary endpoint is parasite prevalence by PCR in all age groups
through a community-based random sampling survey at the
peak of the transmission season.
Successful MDA campaigns require high coverage and good
compliance [41]. Understanding the local context and attitudes
within the trial communities, including the communities’
acceptability of the intervention, is key to achieving the
necessary coverage and compliance to meet the desired clinical
and epidemiological results. For example, healthy individuals,
some of whom may be malaria-infected but asymptomatic, may
not be ready to accept medications for a disease they are
currently not affected by, and this could negatively impact trial
coverage. Engaging communities to establish the most effective,
ethical, and sustainable ways to implement these
community-targeted interventions is vital. Therefore, community
acceptance was assessed using a mixed-method design. During
and after each round of MDA, acceptability was evaluated, and
the findings informed the implementation of subsequent rounds.
To our knowledge, this is the first cluster randomized trial with
a 3-day regimen of 300 µg/kg IVM (high-dose regimen).
Strengths of the study include its design as an adequately
powered cluster randomized trial, the setting in an area with
high coverage of ITNs, IRS, and SMC, and where there is
prompt and effective treatment with ACTs. Another major
strength is the provision of safety data for the high dose IVM
administered with DP. The trial is limited by its inability to
determine the impact of IVM alone as this treatment is
administered with DP, and there is no DP-only arm.
Conclusion
This study will be the first cluster randomized clinical trial of
MDA with IVM plus DP. The results will provide evidence on
the effect of MDA with IVM plus DP on malaria transmission.
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